A BILL 
To require executive agencies to purchase pharmaceuticals 
from the United States, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Securing America’s 
4
Pharmaceutical Supply Chain Act’’. 
5
SEC. 2. REQUIREMENT TO PURCHASE PHARMACEUTICALS 
6
FROM THE UNITED STATES. 
7
(a) IN GENERAL.—Except as provided in subsection 
8
(b), the head of an executive agency may only purchase 
9
00:38 Jul 13, 2021
H3683
2 
•HR 3683 IH
a covered drug if the drug is over 50-percent sourced, 
1
manufactured, and assembled in the United States. 
2
(b) EXCEPTION.—The head of an executive agency 
3
may waive the requirement of subsection (a)— 
4
(1) if the covered drug is not available in suffi-
5
cient quantity or quality as over 50-percent sourced, 
6
manufactured, and assembled in the United States; 
7
or 
8
(2) during an emergency period (as defined in 
9
section 1135(g)(1)(A) of the Social Security Act (42 
10
U.S.C. 1320b–5(g)(1)(A))). 
11
(c) MODIFICATIONS TO TRADE AGREEMENTS.— 
12
(1) IN GENERAL.—Not later than 30 days after 
13
the date of the enactment of this Act, the United 
14
States Trade Representative shall modify United 
15
States product coverage under all free trade agree-
16
ments and the World Trade Organization Agreement 
17
on Government Procurement to exclude coverage of 
18
essential medicines and medical countermeasures. 
19
(2) MODIFICATION
OF
WAIVERS.—Subsequent 
20
to the modifications made under paragraph (1), the 
21
United States Trade Representative shall make any 
22
necessary corresponding modifications of existing 
23
waivers under section 301 of the Trade Agreements 
24
Act of 1979 (19 U.S.C. 2511). 
25
00:38 Jul 13, 2021
H3683
3 
•HR 3683 IH
(3) NOTIFICATION TO THE PRESIDENT.—Sub-
1
sequent to the modifications made under paragraphs 
2
(1) or (2), the United States Trade Representative 
3
shall notify the Director of the Office of Manage-
4
ment and Budget. 
5
(d) DEFINITIONS.—In this section: 
6
(1) COVERED DRUG.—The term ‘‘covered drug’’ 
7
means a drug (including the active pharmaceutical 
8
ingredients thereof) marketed in the United States 
9
pursuant to an approval or licensure under sub-
10
section (c) or (j) of section 505 of the Federal Food, 
11
Drug, and Cosmetic Act (21 U.S.C. 355) or under 
12
subsection (a) or (k) of section 351 of the Public 
13
Health Service Act (42 U.S.C. 262). 
14
(2) EXECUTIVE AGENCY.—The term ‘‘executive 
15
agency’’ has the meaning given that term in section 
16
133 of title 41, United States Code. 
17
(3) 
UNITED
STATES.—The 
term 
‘‘United 
18
States’’ means each of the several States, the Dis-
19
trict of Columbia, and each territory or possession of 
20
the United States. 
21
(e) SEVERABILITY CLAUSE.—If any provision of this 
22
Act (or the application of that provision to particular per-
23
sons or circumstances) is held invalid, the remainder of 
24
00:38 Jul 13, 2021
H3683
4 
•HR 3683 IH
this Act (or the application of that provision to other per-
1
sons or circumstances) shall not be affected. 
2
(f) EFFECTIVE DATE.—The provisions of this section 
3
shall apply beginning on the date that is one year after 
4
the last day of the emergency period (as defined in para-
5
graph (1)(B) of section 1135(g) of the Social Security Act 
6
(42 U.S.C. 1320b–5(g)). 
7
Æ 
00:38 Jul 13, 2021
H3683
